Second Annual BioNJ Diagnostics & Personalized Medicine Innovation Summit Taking Place at Sanofi

 Life Science Industry Leaders and Innovator Companies Meet to Network and Identify Partnership Opportunities that Advance Personalized Medicine

TRENTON, NJ (May 8th, 2013)— BioNJ, the trade association for New Jersey’s biotechnology industry, is hosting its biggest and most interactive event of the year for companies involved in diagnostics and personalized medicine on June 6, 2013 at Sanofi’s US headquarters in Bridgewater, NJ.

Expanded this year due to the success of last year’s inaugural event, the 2013 BioNJ Diagnostics & Personalized Medicine Innovation Summit will bring together leaders from major global biotechnology and pharmaceutical companies, diagnostics companies and emerging “innovator” companies for a full-day, interactive summit meeting.

We were delighted with the level of interest and participation in last year’s event,” said Debbie Hart, President of BioNJ. “So this year we are doing it bigger and better, extending the agenda to a full day and bringing in more first-class speakers from all key constituencies involved with diagnostics and personalized medicine. The BioNJ Diagnostics & Personalized Medicine Innovation Summit has quickly become a ‘must-attend’ event for anybody interested in this exciting new frontier of medicine, where a lot of New Jersey companies are leading the way.

Part of BioNJ’s ongoing Diagnostics & Personalized Medicine Initiative, the focus of this summit is to help participants identify opportunities for partnership, funding and growth while updating them on the latest trends, developments and challenges in the evolution and adoption of personalized medicine. All companies and individuals with an interest in diagnostics and personalized medicine are welcome to attend this event. The Summit will include company presentations and opportunities for one-on-one communication and interaction between leading global pharmaceutical and biotechnology companies, emerging diagnostics companies, funding organizations and life sciences company business development professionals.

Keynote speakers at the 2013 Summit include leaders from global life sciences companies as well as the investment community:

G. Steven Burrill
Chief Executive Officer, Burrill & Company

Elias Zerhouni, MD
President, Global R&D, Sanofi

In addition to keynote speakers, the agenda includes a series of moderated interactive panel discussions focused on research and commercialization challenges in diagnostics and personalized medicine.

Sanofi is fully committed to researching, developing and introducing new products and technologies that deliver on the promise of personalized medicine, and we are excited to be part of this BioNJ event,” said Marc Bonnefoi, DVM, Ph.D., Head of the North America R&D Hub and Vice President of Disposition, Safety and Animal Research Scientific Core Platform at Sanofi, and a Board Member of BioNJ. “Better patient outcomes through more precise diagnostics, targeted therapies, increased efficiencies in healthcare delivery, and lower healthcare costs are just a few examples of how personalized medicine could transform healthcare, and our organization is working hard worldwide to contribute to this transformation.

The BioNJ Diagnostics and Personalized Medicine Committee, which has created the BioNJ Diagnostics & Personalized Medicine Innovation Summit, is also planning additional events focusing on diagnostics and personalized medicine, and will be announcing details for future events on its web site,

About the BioNJ Diagnostics Committee

The BioNJ Diagnostics and Personalized Medicine Committee was created to advance personalized medicine through diagnostics by identifying and supporting partnerships with industry, academic, government and investors in the State of New Jersey.

The goal of the committee is to define and accelerate new areas of diagnostics, such as in vivo and in vitro tests, biomarkers, imaging, information systems and other innovative technologies.

About BioNJ

With more than 300 member companies, BioNJ is singularly focused on the growth and prosperity of New Jersey’s biotechnology cluster.  Founded in 1994 by New Jersey industry CEOs, BioNJ serves as the voice of biotechnology companies located in New Jersey, seeks to advance their economic growth and development and works to encourage new and established companies from around the world to locate in New Jersey. BioNJ represents companies engaged in biopharmaceutical, biomedical, bioagricultural and bioremedial endeavors.